TAK-003 (Qdenga) Dengue Vaccine, Advantages, Challenges

Takeda’s tetravalent dengue vaccine, TAK-003 (called ‘Qdenga’), recently received clearance from the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) for use among individuals aged 4 to 60 years.

About TAK-003 (Qdenga) Dengue Vaccine 

• TAK-003 (Qdenga) is a dengue vaccine developed by the Japanese pharmaceutical company Takeda. 
• It is a tetravalent dengue vaccine, designed to provide protection against all four dengue virus serotypes (DENV-1 to DENV-4).
• It is a disease-modifying vaccine, meaning it reduces severity but does not fully prevent infection. 
• It has been tested on more than 28,000 participants globally and is already approved in over 40 countries.
• It has been approved in India by the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) for individuals aged 4 to 60 years.

TAK-003 (Qdenga) Dengue Vaccine Advantages 

The approval of TAK-003 (Qdenga) Vaccine marks an important step in strengthening India’s dengue control strategy. It represents a shift from a reactive to a more preventive approach. 

• Unlike earlier dengue vaccines, it does not require pre-vaccination screening for prior dengue infection, making it easier to administer in real-world conditions.
• The vaccine has demonstrated good safety and strong protection against severe dengue and hospitalisation. 
• In a country like India, where healthcare systems often face pressure during dengue outbreaks, even a moderate reduction in severe cases can significantly reduce hospital burden and improve health outcomes, especially among children and adolescents.

‹ ›

TAK-003 (Qdenga) Dengue Vaccine Challenges and Limitations

While TAK-003 (Qdenga) Vaccine represents a significant advancement in dengue control, it is important to understand its limitations and the challenges associated with its use in the Indian context.

• Uneven effectiveness across serotypes:  Dengue is caused by four different serotypes (DENV-1 to DENV-4), and protection against one does not ensure protection against others. In some cases, it may even increase the risk of severe disease on later infection, making vaccine development complex. TAK-003 (Qdenga) vaccine shows strong effectiveness against DENV-2 and reasonable protection against DENV-1, but its effectiveness against DENV-3 and DENV-4 appears to be lower, especially in people who have never had dengue before. This is important for India because all four serotypes are present, and DENV-3 is increasing, contributing around 20-30% of cases in some regions. This may reduce the vaccine’s overall effectiveness at the population level.

• Limited Impact on Transmission: TAK-003 is a disease-modifying vaccine rather than a transmission-blocking one. It reduces the severity of illness but does not prevent infection entirely, which means dengue outbreaks are likely to continue and vector control measures will remain indispensable.

• Cost and Accessibility Concerns: The vaccine requires two doses, and the total cost is expected to be Rs 6,000-12,000, which raises concerns about affordability and access, especially for poorer populations.

India’s Indigenous Dengue Vaccine Pipeline

TAK-003 (Qdenga) Vaccine may represent the first major step in India’s dengue vaccination efforts, but it is not the final solution. 

• India is developing an indigenous dengue vaccine, ‘DengiAll’, in collaboration with Panacea Biotec and Indian Council of Medical Research (ICMR). 
• DengiAll is based on the U.S. National Institutes of Health (NIH) TV003 platform.
• It is a single-dose vaccine designed to provide balanced protection against all four serotypes. 
• Early data from similar vaccines indicate strong protection against severe dengue. 
• If successful, DengiAll could be available in India by 2027, offering an improved solution for large-scale public health deployment.

Way Forward 

A multi-pronged strategy combining vaccination, surveillance, and vector control will be essential for sustainable dengue control in India.

• India should focus on integrating vaccination with existing public health measures. 
• TAK-003 can be used to reduce severe dengue cases and hospitalisation, particularly in high-burden regions, but it should not be seen as a standalone solution. There is a need to strengthen vector control measures such as eliminating mosquito breeding sites, insecticide use, and public awareness campaigns, as the vaccine does not prevent transmission and outbreaks may continue.
• Ensuring affordability and wider access will be important for improving coverage, especially among vulnerable populations.
• At the same time, post-marketing surveillance must be prioritised to assess real-world effectiveness across regions and serotype patterns. 
• In the long term, India should remain open to adopting improved vaccines such as DengiAll, which may offer more balanced protection.